# HER2/EGFR in Cancer Research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/her2-egfr-in-cancer-research-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,349,437 |
| Description | This cluster of papers focuses on the use of HER2-targeted therapies, such as trastuzumab and pertuzumab, in the treatment of HER2-positive breast cancer. It explores the mechanisms of action, resistance, and combination therapies involving chemotherapy and monoclonal antibodies. The cluster also delves into the role of EGFR, neuregulin 1, and ADAM metalloproteinases in HER2 signaling and breast cancer progression. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | https://openalex.org/T10755 |
| Works | 68,447 |

## Topic researchers

Showing 12 of 20.

- [Walter C. Willett](https://scholariq.org/researchers/walter-c-willett/)
- [Stacey Gabriel](https://scholariq.org/researchers/stacey-gabriel/)
- [Peer Bork](https://scholariq.org/researchers/peer-bork/)
- [Bert Vogelstein](https://scholariq.org/researchers/bert-vogelstein/)
- [Gad Getz](https://scholariq.org/researchers/gad-getz/)
- [Elaine R. Mardis](https://scholariq.org/researchers/elaine-r-mardis/)
- [Robert A. Weinberg](https://scholariq.org/researchers/robert-a-weinberg/)
- [Peter Jüni](https://scholariq.org/researchers/peter-juni/)
- [John Q. Trojanowski](https://scholariq.org/researchers/john-q-trojanowski/)
- [Todd R. Golub](https://scholariq.org/researchers/todd-r-golub/)
- [Matthew Meyerson](https://scholariq.org/researchers/matthew-meyerson/)
- [Hagop M. Kantarjian](https://scholariq.org/researchers/hagop-m-kantarjian/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.